WO2011070573A1 - Membranes pour traitement antimicrobien de l'eau et leur production - Google Patents

Membranes pour traitement antimicrobien de l'eau et leur production Download PDF

Info

Publication number
WO2011070573A1
WO2011070573A1 PCT/IL2010/001034 IL2010001034W WO2011070573A1 WO 2011070573 A1 WO2011070573 A1 WO 2011070573A1 IL 2010001034 W IL2010001034 W IL 2010001034W WO 2011070573 A1 WO2011070573 A1 WO 2011070573A1
Authority
WO
WIPO (PCT)
Prior art keywords
membrane
peptide
antimicrobial
water treatment
tether
Prior art date
Application number
PCT/IL2010/001034
Other languages
English (en)
Inventor
Roni Kasher
Ze'ev Ronen
Ehud Benin
Original Assignee
Ben-Gurion University Of The Negev Research And Development Authority
Bar-Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben-Gurion University Of The Negev Research And Development Authority, Bar-Ilan University filed Critical Ben-Gurion University Of The Negev Research And Development Authority
Priority to EP10835606.4A priority Critical patent/EP2509614A4/fr
Priority to US13/514,103 priority patent/US9175036B2/en
Publication of WO2011070573A1 publication Critical patent/WO2011070573A1/fr
Priority to IL220181A priority patent/IL220181B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D65/00—Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
    • B01D65/08—Prevention of membrane fouling or of concentration polarisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081—After-treatment of organic or inorganic membranes
    • B01D67/0093—Chemical modification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081—After-treatment of organic or inorganic membranes
    • B01D67/0093—Chemical modification
    • B01D67/00931—Chemical modification by introduction of specific groups after membrane formation, e.g. by grafting
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/14—Dynamic membranes
    • B01D69/141—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
    • B01D69/142—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes with "carriers"
    • B01D69/144—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes with "carriers" containing embedded or bound biomolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2321/00—Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/16—Use of chemical agents
    • B01D2321/168—Use of other chemical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2323/00—Details relating to membrane preparation
    • B01D2323/38—Graft polymerization
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2325/00—Details relating to properties of membranes
    • B01D2325/48—Antimicrobial properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025—Reverse osmosis; Hyperfiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/027—Nanofiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration

Definitions

  • TFC thin film composite
  • RO reverse osmosis
  • NF nanofiltration
  • UF ultrafiltration
  • Biofilm is an aggregate of microorganisms in which cells adhere to each other and/or to a surface. These cells are frequently embedded in a self-produced matrix of extra-cellular polymeric substance (also referred to as slime) .
  • Biofilm may form on living or non-living surfaces, such as on membranes used in water treatment processes, where there is a continuous supply of nutrients, a supply which promotes microorganism reproduction and accelerates bacterial growth.
  • Another strategy involves modification of the membrane surface to render it less susceptible to biofouling.
  • the hydrophilic character of the membrane surface ' can be increased by graft polymerization using hydrophilic monomers onto RO and NF membranes (e.g., Belfer et al . Journal of Membrane Science 55-64, 239, 2004). These methods, while improving membrane resistance to organic fouling, have not been successful in preventing biofouling.
  • antimicrobial peptides has been suggested in industrial processes which include the use of RO membranes (US 20020051819, US 20030050247, US 20030194445, US 20050065072 and US 20060166883) .
  • Antimicrobial peptides are small molecular weight proteins with broad spectrum antimicrobial activity against bacteria, viruses, and fungi. These evolutionarily conserved peptides are produced in all types of living organisms and serve as part of each organism's innate immunity. AMPs are usually positively charged, enabling them to strongly bind to the negatively charged outer cell membrane of prokaryotes, thereby enhancing antimicrobial activity.
  • these modified membranes have proven antibacterial activity as well as stability, and can be used in both saline and non-saline environments, thus rendering them most suitable for a wide variety of water purification applications which are susceptible to biofouling and biofilm formation.
  • an antimicrobial water treatment membrane comprising a water treatment membrane, covalently attached to one or more antimicrobial peptides or derivatives thereof, either directly or via tethers (spacers) and/or linkers.
  • Water treatment membranes are classified according to their permeability and uses, as detailed above.
  • the present invention is suitable to Reverse Osmosis (RO) membranes, Nano Filtration (NF) membranes, and also to Ultra Filtration (UF) and Micro Filtration (MF) membranes, as long as these membranes can covalently link, or can be modified to link, to an antimicrobial peptide (AMP) either directly or via a tether molecule.
  • RO Reverse Osmosis
  • NF Nano Filtration
  • UF Ultra Filtration
  • MF Micro Filtration
  • the water treatment membrane of the present invention is an RO or NF membrane.
  • the membrane is selected from thin film composite (TFC) membranes, cellulose acetate membranes, other esters of cellulose, ultrafiltration membranes such as polyethersulfone (PES) , polysulfones , chlorinated polyvinyl chloride (PVC) or polyvinylidene fluoride (PVDF) .
  • TFC thin film composite
  • PES polyethersulfone
  • PVC chlorinated polyvinyl chloride
  • PVDF polyvinylidene fluoride
  • TFC membrane defines a semi-permeable membrane composed of a polymer constructed in the form of a film from two or more layered materials.
  • TFC membranes sometimes termed TFM, are mainly used in water purification or water desalination systems (in reverse osmosis (RO) , nanofiltration (NF) and ultrafiltration (UF) applications) but are also used in chemical applications such as batteries and fuel cells.
  • RO reverse osmosis
  • NF nanofiltration
  • UF ultrafiltration
  • TFC membranes for RO and NF applications may be prepared from polyethyleneimine/toluene-diisocyanate , polyepiamine, polypiperazine-amide, polypiperazine- trimesamide and many others [see a review: Petersen, R. J. Journal of Membrane Science 83, 81-150 (1993)].
  • the most common TFC membrane for RO and NF membranes is an aromatic polyamide membrane, namely that the outer film is made of an aromatic polyamide and therefore has free carboxylic groups attached to it.
  • carboxylic groups can then link directly to a peptide via its amine side to form amide bonds, or it can be used to attach other chemical groups to it, so as to enable covalently attaching a peptide or a tether linked to a peptide, thereto.
  • TFC membrane for Ultrafiltration (UF) membranes is a polysulfone or polyethersulfone membrane, namely that the outer film is made of a polysulfone.
  • a peptide or a tether can be attached to polyethersulfone UF membrane according to the present invention by initially performing redox- initiated graft co-polymerization with methacrylic acid/PEGMA on the polyethersulfone membrane, as described in Scheme 7.
  • Graft polymerization of UF polyethersulfone membranes was previously done [Belfer S, Fainchtain R, Purinson Y, Kedem O. Journal of Membrane Science 172 Issue 1-2 Pages: 113-124].
  • immobilization on the UF membrane may proceed according to the multivalent immobilization in scheme 8 or more efficiently in Scheme 9.
  • PAN polyacrylonitrile
  • Graft polymerization of UF polyacrylonitrile membranes was previously done in our department by S. Belfer [S. Belfer. REACTIVE & FUNCTIONAL POLYMERS 54, Pages: 155-165] .
  • Cellulose Acetate membranes may also be used in the present invention.
  • antimicrobial peptide includes both naturally occurring and synthetic peptides, having an antimicrobial activity, which is the ability to prevent, inhibit, reduce or destroy one or more microorganism.
  • the present invention includes peptides having an antimicrobial activity against microorganisms causing the formation of biofouling or biofilm formation.
  • antimicrobial peptides suitable for the present invention are preferably those that have the ability to prevent, inhibit, reduce or destroy biofilm- forming microorganisms.
  • microorganism refers to bacteria (Gram-positive or Gram-negative) , fungi, alga or protozoa. Therefore, biofilm-forming microorganism include bacteria, yeast, fungi and alga and protozoa that are capable of forming biofilm or of causing biofouling.
  • biofilm refers to biological films that develop and persist at interfaces in aqueous environments. Biofilm forms when bacteria adhere to surfaces in moist environments by excreting a slimy, glue-like substance made of sugary molecular strands, collectively termed "extracellular polymeric substances" or "EPS.”
  • EPS extracellular polymeric substances
  • Biofilm-forming bacteria include, but are not limited to, Listeria, Salmonella, Campylobacter, Escherichia coli, Pseudomonas, lactic acid-producing bacteria,
  • the antimicrobial activity of a peptide against a biofilm- forming microorganism can be determined by a method depending on the specific film- forming microorganism in question, and is typically provided as an IC 50 value.
  • IC 50 refers to the concentration of a compound (in this case the antimicrobial peptide) needed to reduce biofilm growth or accumulation of certain microorganism by 50% in vitro or in situ.
  • the IC 50 is determined by an essay, suitable for the specific film- forming microorganism in question.
  • the Enterobacter assay which is described in detail in the methods section below, was used to determine the antimicrobial activities of the tested peptides.
  • the antimicrobial peptides suitable for the present invention are characterized by an IC 50 against at least one species of biofilm- forming microorganism, of up to 200 g/ml, preferably of up to 150 ⁇ g/ml, more preferably of up to 100 g/ml and most preferably of up to 50 pg/ml .
  • the antimicrobial peptides of the present invention had IC 50 values as low as 10-11 g/ml (for All D C- odelin-1 and C- odelin-1, respectively) and even 4 g/ml (for C-Modelin-l-pAla) to the film-forming Enterobacter, under the assay described in 96-microtitter plates (see Experimental section hereinbelow) .
  • a PEGylated peptide (HS-PEG-D-Modelin-1) was prepared, and was found to have an IC 50 as low as 0.4 - 0.62ug/ml , much lower than the D-Modelin-1. This means that the PEG tether increased the antimicrobial effect of peptide D-Modelin-1.
  • Naturally occurring antimicrobial peptides have been isolated from biological sources such as bacteria, insects, amphibians and mammals and are thought to represent inducible defense proteins that can protect the host organism from bacterial infection.
  • Naturally occurring antimicrobial peptides include the gramicidins, magainins, mellitins, defensins and cecropins (see, for example, Maloy and Kari, Biopolymers 37:105-122 (1995); Alvarez-Bravo et al . , Biochem. J. 302:535-538 (1994); Bessalle et al .
  • AMPs taken from marine animal species are used.
  • An antimicrobial peptide can also be an analog or derivative of a natural peptide.
  • Suitable derivatives of natural antimicrobial peptides include peptides composed of the methyl- derivatives of the respective amino acids comprising the peptide, or the D-derivatives of these amino acids.
  • Example 1 that all - (D) -amino acid analogs of natural peptides, N-methyl peptides and peptides containing unnatural amino acids in the C-terminal were stable against proteolysis and are therefore preferred peptides for use in the present invention. This is especially important as during biofilm formation, bacteria excrete proteases which may degrade the peptides and therefore it is advantageous that the antimicrobial peptides are also resistant to proteolysis.
  • Resistance to proteolysis can be determined according to trypsin, chymotrypsin or pronase E assay, as detailed below in the Methods section, namely by adding to each 90 ⁇ of peptide solution, 10 ⁇ of enzyme solution, containing either a mixture of 0.5 pg trypsin (0.05 mg/ml) and 0.5 pg chymotrypsin (0.05 mg/ml) or 4 pg pronase E (0.4 mg/ml) in 0.001M HC1. The enzymatic degradation of the peptide is monitored at controlled temperature of 25°C. A peptide can be considered to be resistant to proteolysis if it withstands this assay for at least 1 week, maintaining at least 90% of its initial concentration after this period.
  • an antimicrobial water treatment membrane comprising a water treatment membrane, covalently attached to one or more antimicrobial peptides or derivatives thereof via one or more tether molecules, wherein the antimicrobial peptide:
  • covalently attached generally refers to an attachment of one molecular moiety to another molecular moiety through covalent chemical bonds. This term does not exclude the existence of other levels of chemical and/or physical bonding, such as hydrophobic bonds, hydrogen-hydrogen bonds etc, in addition to the existence of covalent bonding. Furthermore, the term “covalently attached” may also include strong complex-ligand attachment, as long as it is stable in aqueous conditions such as Avidin/biotin complexation .
  • Suitable covalent bonds that may form between the membrane and the peptide, or between the membrane and the tether, or between the tether and the peptide include, but are not limited to:
  • Additional possible bonds include an azide-alkyne bond, a hydrazine-aldehyde bond, and an Avidin-biotin (host-guest) complexation.
  • the membrane is a polyamide and has free carboxyl groups which attach directly with the N- terminal side of a peptide, the covalent bond between them would be an amide bond.
  • a similar bond forms between a polyamide membrane and a tether having an amine terminal group .
  • the membrane or tether linked to it are attached to a maleimide (MI) molecule, which then attaches to a thiol group on the tether or on the peptide, a covalent thioether bond is formed.
  • MI maleimide
  • the AMP is intentionally modified to include a thiol group as a terminal group.
  • this is conducted by adding a Cysteine (Cys) residue, at the AMP amino terminal.
  • Additional modifications include using an all-D peptide or adding a linking group, such as maleimine (MI) to the AMP.
  • MI maleimine
  • a combination of AMPs may also be used.
  • microbicidally active refers to a peptide having an IC 50 of up to 200 pg/ml, preferably up to 150 pg/ml, more preferably of up to 100 pg/ml and most preferably of up to 50 g/ml against at least one species of biofilm- forming microorganisms.
  • high concentrations of salt refers to a concentration of 3% NaCl .
  • suitable AMPs for use in saline environments include, but are not limited to, a modified Modelin-1 peptide and a modified Hexpeptide-4 .
  • AMPs can be attached directly to the water treatment membranes, they are preferably attached to it via a tether molecule.
  • the tether allows a degree of freedom and movement to the peptides, such that contact with the microorganism (for example, the bacteria) is enabled and creates a "brush" effect that increases its efficiency against biofilm forming microorganisms.
  • the tether should also help position the peptide relative to the membrane, mainly to maintain a distance between the peptide and membrane surface.
  • an antimicrobial water treatment membrane comprising a water treatment membrane, covalently ' attached to one or more antimicrobial peptides or derivatives thereof via one or more tether molecules .
  • tether as used herein, is used interchangeably with the terms “spacer” or “arm” and refers to a typically long molecule, such as oligomer or polymer, that is covalently attached to, and interposed between the peptide, or a linker attached thereto, and the membrane substrate or a linker attached thereto, as an alternative to direct attachment between the peptide and the membrane .
  • the tether molecule is typically a molecule such as an oligomer or polymer, having a molecular weight (MW) of at least 300 grams/mol, but more preferably its molecular weight is higher, namely at least 500 grams/mol.
  • MW molecular weight
  • Many useful tethers are found in the range of 500-2000 grams/mol.
  • the tethers used in the Examples section below included a long PEG arm, for example, such as PEG-diamine 2000 as well as PEG-diamines of between 800 - 7500 gr/mol may be used.
  • the tether includes a JeffamineTM arm, typically, effamine 300, Jeffamine 500, or Jeffamine 800.
  • the tether forms a minimal distance between the membrane and the AMP.
  • This minimal distance can be correlated to a maximal, or extended, length of the tether, in an aqueous solution environment being at least 1.5 nanometers long, more preferably at least 3 nanometers long, yet more preferably at least 5 nanometers long.
  • extended length refers to the theoretical maximal length of the polymer, in its stretched form, under aqueous conditions. It is calculated by molecular dynamics calculations.
  • the calculated extended length was 27.3 nm for using PEG3000 -diamine tether, 18.2 nm for using PEG2000- diamine tether, 5.1 nm for JeffAmine800 tether, 3.2 nm for JeffAmine500 tether, 1.92 nm for JeffAmine300 tether.
  • the ratio between the molecular weight and the extended (maximal) length of the tether, namely MW/EL, is preferably lower than 1,200 grams/mol per 1 nanometer.
  • the calculated ratio between the molecular weight and the extended length was 172 grams/mol per 1 nm for the JeffAmine tether and ⁇ 120 grams/mol per 1 nm for the PEG tethers .
  • an antimicrobial water treatment membrane comprising a water treatment membrane, covalently attached to one or more antimicrobial peptides or derivatives thereof via one or more tether molecules, wherein this tether:
  • - is an oligomer or a polymer having a molecular weight (MW) of at least 300 grams/mol,
  • - has an extended length (EL), in an aqueous environment, of at least 1.5 nanometers; and - has a ratio between said and said EL which is lower than 1,200 grams/mol per 1 nanometer.
  • tethers While in most cases tethers are synthetic polymers, they can also be bio-polymers, such as DNA, polysaccharides (and oligosaccharides), RNA, etc.
  • tether polymers include, but are not limited to, Poly Ethylene Glycol (PEG) , poly- acrylamide, poly- (D) -lysine, poly-methacrylic acid, or a co-polymer of methacrylic acid and other acrylate monomer, diamine polymers such as JeffAmineTM, poly-maleic anhydride or copolymer of (ethylene) and (maleic anhydride) , a lysine dendrimer or any other dendrimer and polyethylene- imine .
  • PEG Poly Ethylene Glycol
  • D D
  • -lysine poly-methacrylic acid
  • co-polymer of methacrylic acid and other acrylate monomer diamine polymers such as JeffAmineTM, poly-maleic anhydride or copolymer of (ethylene) and (maleic anhydride) , a lysine dendrimer or any other dendrimer and polyethylene- imine .
  • the tether molecule must have at least two terminal groups which are capable of linking to at least one peptide on one side and to the membrane on the other side, and the membrane and peptide must also have at least one such group each.
  • the tether should have at least two terminating groups, each being independently selected from a maleimide (MI) group, 6 -aminohexanoic acid, a thiol group, an azide group, an amine group, a carboxyl group or an acetylene group .
  • MI maleimide
  • 6 -aminohexanoic acid 6 -aminohexanoic acid
  • thiol group an azide group
  • an amine group a carboxyl group or an acetylene group
  • both the membrane and the peptide should also independently have at least one terminating group being selected from a maleimide (MI) group, 6 -aminohexanoic acid, a thiol group, an azide group, an amine group, a carboxyl group or an acetylene group .
  • MI maleimide
  • 6 -aminohexanoic acid 6 -aminohexanoic acid
  • a thiol group an azide group
  • an amine group a carboxyl group or an acetylene group
  • suitable covalent bonding between the tether and the membrane and/or the peptide include an amide bond, a thioether bond, a carbon-carbon covalent bond and a carbon-nitrogen bond. Therefore, some examples of suitable terminal groups include, but are not limited to, carboxyl (CO), amine, thiol and imides . In many examples a diamine tether or an amine-terminated and thiol-terminated tethers were used.
  • HydraLink It is based on a reaction between hydrazine and aldehyde: 2-hydrazinopyridyl moiety on one site, and a benzaldehyde moiety on second site.
  • Avidin/biotin a ligation between biotin group (see draw) and avidin.
  • Avidin is a protein which can be bound either via its amine or carboxyl groups.
  • Biotin can be bound via its carboxyl group.
  • the tether and/or membrane and/or peptide can be easily modified, mostly "off membrane” to introduce the suitable terminating groups into their respective positions, as known to a person skilled in the art.
  • the tethers may also be multivalent molecules, such as polymers prepared by graft polymerization or branched polymers have a multitude of functional groups, to which the peptides or linkers may be later attached.
  • Multivalent tethers are advantageous in that they provide a locally- peptide-rich environment in the final product due to high peptide loading on the membrane surface.
  • specific linking groups are used to attach the tether to the AMP and/or to attach the tether to the membrane and/or to attach the AMP to the membrane, and to provide the required regio- selectivity of binding of the antimicrobial peptide.
  • the peptide is linked via a specific site on the peptide chain, usually, but not necessary, near its N-terminal.
  • linker is also referred to interchangeably by the term “linking group” or "binding group” and is typically a small molecule containing a suitable binding group. However, the term also encompasses the binding group itself as a chemical group.
  • suitable linkers include, but are not limited to molecules including a maleimide (MI) group, 6- aminohexanoic acid, amine, thiol, or azide.
  • suitable linkers may contain an acetylene group to allow, for example, "click chemistry" attachment.
  • a modified tether such as a tether attached to a linking group or binding group, as described herein, will typically remain a "tether” as per the definitions provided hereinabove.
  • a PEG tether attached to an MI linker is also defined as a tether for the purpose of this invention, since it remains a polymer or oligomer, having the minimal molecular weight (MW) of 300 grams/mol, as long as it still follows the requirements of a minimal extended length (EL) and a maximal MW/EL ratio.
  • the polymers or oligomers comprising the tether may be homopolymers and copolymers of all sorts, and may include blocks of oligomers and/or or blocks of polymers linked by one or more linking groups, as suggested herein.
  • Some additional preferred embodiments of the invention include the following specific antimicrobial water treatment membranes, prepared by the inventors as described herein, having structures I -IV shown below, wherein for each structure j, k, 1, m and n are integers independently chosen to be larger than 1, and the peptide is selected from hexapeptide-4, Modelin-1 and All-D- odelin-1.
  • the present invention provides novel membranes and a method for water treatment processes using these AMP immobilized membrane to avoid biofouling during water treatment processes.
  • the one or more an imicrobial peptides were covalently attached to the membrane, either directly or via a tether and/or linker molecules to obtain the antimicrobial membranes described herein.
  • a process for preparing an antimicrobial water treatment membrane comprising covalently attaching one or more antimicrobial peptides or derivatives thereof to a water treatment membrane, either directly or via a tether molecule.
  • the tether and the peptide are as defined hereinabove .
  • the linking of the peptide to the linker or tether molecules can be via the amine side of the peptide (N- terminus) , or via the carboxyl side thereof (C-terminus) or via a side chain.
  • the peptide shall be linked to the tether or linker at its N-terminus.
  • the thiol group of a cysteine amino acid linked to the N-terminus can be natural or can be synthetically added to the N-terminus of the peptide via a Cys amino acid or via another modification.
  • the antimicrobial water treatment membranes of the present invention there are several synthetic routes, but all are based on covalently attaching one or more antimicrobial peptides to a water treatment membrane, optionally via a tether molecule and/or via a linker attaching the peptide to the tether or/linker or attaching the tether/linker to the membrane surface .
  • the preparation of the modified antibacterial water treatment membranes can be affected by one of several routes, some of which are detailed below:
  • the linker may be linear or branched, and the tether may be single valent or multivalent .
  • the moiety AMP-L can be regarded as a modified peptide
  • the moiety M-L can be regarded as a modified membrane
  • the moiety T-L can be regarded as a modified tether
  • the moiety ,T-AMP can be defined as a tethered AMP.
  • Scheme 1 illustrates an exemplary scheme of covalent binding of AMPs to an RO-polyamide membrane surface.
  • AMPs are attached to an aromatic po.lyamide (PA) RO membrane through a thiol-binding group which binds an Maleimide (MI) linker bound to PEG-amine tether that is attached to the membrane.
  • PA aromatic po.lyamide
  • MI Maleimide
  • the step of attaching a protected PEG-amine tether to an MI linker is preformed prior to attachment to the membrane ("off membrane”) .
  • the linker-PEG-amine molecule is then attached to the membrane by the use of coupling reagents, so that the linker is free to bind an AMP in a subsequent step.
  • An AMP having a thiol-binding group is then attached to the linker- PEG amine tether- membrane. Both steps of attaching the linker-PEG-amine tether to the membrane and attaching the AMP to the linker-PEG amine-tether, are done on the membrane.
  • Schemes 2A and 2B show another exemplary attachment of peptides to a tethered RO membrane.
  • Scheme 2B (AMP-L-T-M) Schemes 2A and 2B show a three- steps process for modifying the membrane: "off membrane", an SH (thiol) group is added to the peptide to obtain a SH-peptide. Then, a di-amine polymer tether is attached to the membrane in the presence of coupling reagents.
  • the tether is a polymer, and in many cases is chosen to be a long JeffamineTM arm or a PEG-diamine molecule, as shown in the scheme.
  • coupling reagents examples include l-ethyl-3- (3- (dimethylamino) propyl) carbodiimide hydrochloride (EDC) and N-hydroxy- sulfosuccinimide (sulfoNHS) .
  • a linker such as MI -hexanoic acid molecule is then attached to the immobilized tether, in the presence of coupling reagents.
  • a peptide is then attached to the linker via the thiol group of the peptide C-terminal cysteine.
  • the MI group on the tether-memrane then reacts with the thiol group on an antibacterial peptide, typically with the thiol on the cystein residue at the N- terminus of the peptide.
  • the MI-cys reaction is carried out without coupling reagents but in the presence of nitrogen, or oxygen free atmosphere, so as to keep an inert environment, to prevent oxidation of the cystein residue and increase the yield; however, the process can be carried out under atmospheric conditions as well.
  • Schemes 3 and 4 show another type of immobilization process to obtain a Membrane-linker-tether-peptide system.
  • One example is shown in Scheme 3, which presents an efficient 2-steps synthesis on the membrane, whereas amine-maleimide linker is used in the 1 st step, and PEG- peptide is used in the second step.
  • thiol-tether-peptide (thiol-PEG-all-D-Modelin-1) was synthesized first.
  • the synthesis of thiol-PEG-D-Modelin-1 was performed on solid support (SPPS) , and was successful according to the HPLC and MS analyses of the thiol-PEG-D-Modelin-1 product.
  • Scheme 4 shows another exemplary alternative attachment of peptides to an RO membrane to obtain a membrane-linker-tether-peptide system, having a branched linker .
  • a linker such as maleimide
  • a small molecule such as amino-ethyl-maleimide
  • Branched linkers may be used during this step (for example Bis-Mal-Oc-NH 2 in Scheme 3) .
  • Other branched linkers such as commercially available dendrimers with appropriate end groups, may be used.
  • the use of branched linkers may enhance AMP concentration on the membrane.
  • a peptide is attached to a tether (such as a PEG molecule) off-membrane .
  • the tether has a binding group (e.g., thiol) at its end to enable attachment to the linker which is immobilized to the membrane.
  • the AMP with a thiol -tether at its N- terminal is then attached to the maleimide on the membrane .
  • the linker may be based on click chemistry, for example, using an acetylene and azide group linkers .
  • click chemistry for example, using an acetylene and azide group linkers .
  • an increase of local concentration of the peptides was now achieved by the inventors by multivalent immobilization of AMPs on RO membranes, using two approaches: By graft polymerization, and by dendrimers or multifunctional polymers, as shown in scheme 5, in comparison to linear immobilization.
  • Graft polymerization (e.g., according to the procedure described in Belfer, et al. (1998) Journal of Membrane Science, 139, 175-181) may be used to obtain multi-arms molecular systems on the water treatment membrane, which has multiple copies of a functional group such as carboxyl, amine, thiol, ether or hydroxyl . This system may be used to attach linkers to membranes. Graft polymerization may be used advantageously for attaching linkers to the membrane in a branched manner, hence multiple copies manner.
  • the monomers are selected from the group comprising of acrylate- and methacrylate-derivatives, maleic anhydride, ethylene, ethylene-glycol derivatives vinyl -pyrrolidone, vinyl - derivatives that have carboxyl or amine groups, and styrene derivatives.
  • PEGM Glycidyl methacrylate methacrylate
  • DMAEMA DMAEMA
  • Multifunctional polymers may also be used to immobilize peptides to RO membranes in multivalent system, in the first stage a polymer conjugated to multiple copies of an antimicrobial peptide is created, (see Scheme 11 for example, based on Liu, Z.G., et al . , J. Med. Chem. (2006); Gestwicki, J.E. et al . JACS, (2002)). In the second stage binding the polymer peptide conjugate to the RO membrane surface is done as was described for dendrimers in Scheme 10B.
  • an antimicrobial water treatment membrane in antimicrobial water purification processes comprising sea-water desalination, waste water treatment, brackish water treatment, industrial water treatment and water recycling, wherein the antimicrobial water treatment membrane is the membrane according to the present invention, as described hereinabove.
  • an antimicrobial water purification process comprising contacting a water source selected from sea-water, waste water, brackish water, industrial water, irrigation water and drinking water, with an antimicrobial water treatment membrane according to the present invention, as described hereinabove.
  • Amino acids used for peptide synthesis (L and D configurations) : Fmoc-Ala-OH, Fmoc-D-Ala-OH, Fmoc-Ahx-OH, Fmoc-Arg (Pbf) -OH, Fmoc-As (OtBu) -OH, Fmoc-Cys (Trt) -OH, Fmoc-D-Cys (Trt) -OH, Fmoc-Glu (OtBu) -OH, Fmoc-Gly-OH, Fmoc- Ile-OH, Fmoc-Leu-OH, Fmoc-D-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-D-Lys (Boc) -OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc- Trp(Boc)-OH, Fmoc-D-
  • the amino acids were purchased from Advanced ChemTech (Louisville, Kentucky) , Iris Biotech GmbH (Marktredwitz , Germany) , Novabiochem (Laufelfingen, Switzerland) ,Biosolve (Valkenswaard, The Netherlands) , Chem-Impex International (Wood Dale, Illinois) .
  • Resins used for Solid Phase Peptide Synthesis Rink resin ss, 100-200 mesh, 1% DVB, 0.7 mmol/g; Wang resin ss, 100-200 mesh, 0.6mmol/g; Fmoc-Trp (Boc) -Wang resin, 100-200 mesh, 0.6mmol/g, Fmoc-D-Trp (Boc) -Wang resin, 100-200 mesh, 0.6mmol/g, Fmoc- ⁇ -Ala-Wang resin, 100-200 mesh, 0.22 mmol/gr, [Fmoc-Lys (Fmoc) ] 4 -Lys 2 -Lys-Cys (Acm) - ⁇ -Ala-Wang resin, 200-400 mesh, 1.0 mmol (Fmoc) /gr , Fmoc-Asp (Wang resin) -Amc, 100-200 mesh, 0.65mmol/g.
  • the resins
  • NMP N-methyl-pyrrolidone
  • DMF ⁇ , ⁇ ' -dimethylformamide
  • DCM dichloromethane
  • Acetic anhydride, triisopropylsilane, crystal violet, toluidine blue, orange II, HEPES buffer, ethyl-dimethylaminopropyl-carbodiimide (EDC) and 6 -maleimidohexanoic acid were purchased from Sigma (st. Louis, Missouri) .
  • NHS and AMC were purchased from Chem-Impex International (Wood Dale, Illinois) .
  • DIEA was purchased from Advanced ChemTech (Louisville, Kentucky) .
  • Piperidine, dicyclohexylcarb3odiimide (DCC) , trifluoroacetic acid, pyridine, tert-butyl methyl ether , ethanol , toluene , acetone , acetonitrile and isopropanol were purchased from Bio-Lab (Jerusalem, Israel).
  • 1,2- ethanedithiol was purchased from Acros Organics (Geel, Belgium) .
  • Ninhydrin, dithiothreitol and Jeffamine 50 o were purchased from Fluka (Buchs, Switzerland) .
  • Diamine PEG 2 ooo was purchased from Rapp Polymere (Tubingen, Germany) .
  • Glycerol was purchased from Ridel-de Haen (Seelze, Germany) .
  • 33EDTA purchased from BDH chemicals Ltd (Pool, England).
  • Poly(maleic anhydride) and poly (ethylene-maleic anhydride) were purchased from Polysciences (Warrindton, PA) .
  • Trimethylsilyl diazomethane was purchased from TCI (Tokyo, Japan) .
  • the enzymes caspase 8, ⁇ trypsin (EC 3.4.21.4), chymotrypsin (EC 3.4.21.1) and pronase E (EC 3.4.24.31) were purchased from Sigma (st. Louis, Missouri) .
  • TSB was purchased from Acumedia Manufacturers (Lansing, Michigan) .
  • RTV 186 was purchased from Polymer G'vulot (Kibbutz G'vulot, Israel) .
  • RO membranes FILMTEC SW30HR LE-400 seawater RO and FILMTEC LE-400 high productivity low-energy brackish water RO were gifted from DOW (Midland, Michigan) .
  • ESPAl RO was gifted from Hydranautics (Oceanside, California) .
  • the column was washed with solvent C - 65% ACN in DDW. All solvents were filtered (0.22 ⁇ /0.45 ⁇ ) before use.
  • Preparative HPLC separations were performed either on the above Surveyor HPLC system, or on RP-HPLC that consists of Waters 600 Semi-Prep HPLC controller and quaternary pump (Milford, Massachusetts) equipped with manual injector with loop volume of 5 ml (Rheodyne, Rohnert, California), Spectro monitor 3100 UV/vis detector (Milton-Roy, Ivyland, Pennsylvania) and Gilson FC 204 Fraction collector (Middletori, Wisconsin) .
  • the peptides were dissolved in DDW or ACN/DDW solution and filtered before the HPLC separation. A sample (up to 60 mg of peptide) was injected by manual injector port with 2 or 5 ml loop.
  • Mass spectrometry of synthesized peptides A peptide sample dissolved in 3/1 acetonitrile/water mixture was analyzed by MALDI-TOF mass spectrometry (REFLEX- IV MALDI - TOF mass spectrometer Bruker Daltonics, Bremen, Germany) , by Dr. Mark Karpases from the analytical services and instrumentation unit of Ben-Gurion University of the Negev.
  • ATR-FTIR spectroscopy and estimation of degree of grafting were recorded on a VERTEX 70/80 standard system spectrophotometer, using a KRS crystal (BRUKER Optiks GmbH, Ettlingen, Germany) . The membranes were completely dried overnight in a vacuum desicator prior to the measurement .
  • Quantitative biofilm growth inhibition assay in a 96- wells microti er plate Enterobacter culture (50 ml) was grown in tryptic soy broth media (TBS; prepared according to manufacturer instructions) overnight at 25 °C. On the next day the turbidity of the culture was measured at 600 nm (Biomate 5 UV-Vis spectrophotometer, Thermo Fisher Scientific, Waltham, Massachusetts) and, if necessary, TSB was added to dilute the culture until the OD was 1.
  • the plates were incubated at 25°C overnight. On the next day the plates were gently rinsed 5 times with distilled water to remove the planktonic bacteria and then dried at room temperature for 10 minutes. Then the biofilm on the walls of the wells was dyed by adding 200 ⁇ . of 3% crystal violet (CV) to the wells. After 15 minutes at room temperature, the plates were gently rinsed 5 times with distilled water to remove excess dye and dried at room temperature for 10 minutes (Djordjevic, Wiedmann & McLandsborough 2002) . The dry plates were filled with 200 ⁇ ethanol, ' covered and gently agitated (Duomax 1030 rocking platform shaker, Heidolph, Kelheim, Germany) for 1 hour. The absorbance of extracted color was measured in a plate reading spectrophotometer (Infinite M200, Tecan, Mannedorf, Switzerland) at 595nm.
  • the test measures the carboxyl group concentration on the surface of the membrane, and was used to estimate the degree of modification.
  • the test was based on the published article by Naka ima et al . 1995 [Nakajima, N. 1995, Bioconjugate chemistry, vol. 6, no. 1, p. 123] with various modification; the membranes were glued to glass slides using RTV 186 glue (prepared according to manufacturer instructions- Polymer G'vulot) .
  • the dye was eluted with minimal volume (12-13 ml) of 50% (v/v) acetic acid for 2 hours.
  • the absorbance of the dye was measured at 633 ran (Lambda EZ 201 PerkinElmer spectrophotometer, Waltham, Massachusetts) .
  • a 50% acetic acid solution was used.
  • TB concentrations in 50% acetic acid
  • the surface concentration of the acid groups was calculated based on the membrane area, dye concentration, and volume of the eluting solution.
  • the concentration of carboxyl groups on membrane surface was calculated with the assumption of 1:1 dye: carboxyl group complex . Initially, the concentration of carboxyl groups on the surface of 3 different RO membranes was estimated using Toluidine blue adsorption: ESPA1, FILMTEC S 30HR LE- 400, and FILMTEC LE-400 (brackish water) . The results are presented in Table 1.
  • ESPA1 membrane had the highest concentration of surface carboxyl groups.
  • H-Cys-Ile-Glu- Pro-As -AMC was synthesized by the SPPS method, on a commercially available resin Fmoc-Asp (Wang-resin) -AMC, using standard Fmoc chemistry. The synthesis was carried out automatically, using automated peptide synthesizer. The synthesized peptide was analyzed by RP- HPLC system and its sequence was confirmed by MALDI-TOF MS. The peptide H-Cys-Ile-Glu-Pro-Asp-Amc was immobilized on 2 cm 2 RO membranes (previously washed) via diamine PEG 2 ooo
  • the peptide solution was incubated at 31°C in dark in incubator shaker for 7 days and its fluorescence was measured as membrane solutions.
  • a calibration curve was constructed using the following free Amc concentrations (in HEPES buffer solution): 0.1 ⁇ , 0.2 ⁇ , 0.4 ⁇ , 0.6 ⁇ 0.8 ⁇ , 1.6 ⁇ , 2.4 ⁇ , 3.2 ⁇ , 4 ⁇ .
  • the surface concentration of the immobilized peptides was calculated based on the membrane area, Amc concentration in solution, and volume of the solution .
  • Table 2 shows the fluorescence values obtained for the different modification conditions. 3 hours
  • the cleavage reaction of AMC from a free (unbound) peptide was tracked in parallel by fluorescence detection as a control for the cleavage reaction and fluorescence signal.
  • the fluorescence values after 7 days incubation period were used to calculate the concentrations of the immobilized peptides on the surface of the membranes (Table 3) .
  • Biofilm was grown on different membranes in static conditions in which membranes were immersed in an Enterobacter culture. The cell content of the biofilm that developed on the membranes was exteriorated and evaluated using Bradford reagent for determining protein concentration.
  • membranes were glued with RTV 186 glue to a lcmxlcm glass slides and were incubated in 24 -wells plate, containing Green fluorescent protein (GFP) expressing Pseudomonas aeruginosa culture, for 18 hours (37°C) . Then, the membranes were washed with DDW to remove planktonic bacteria and the formed biofilm was detected by Leica DM 2500 confocal laser scanning microscope (CLSM, Wetzlar, Germany) .
  • GFP Green fluorescent protein
  • lcmxlcm membranes were glued to a 2.6cmx7.6cm glass slide and the slide was placed in a flow cell.
  • GFP expressing Pseudomonas aeruginosa was introduced to the cell and incubated for 1 hour.
  • the planktonic bacteria were washed out and sterile growth media was brought in to the cell with 50 ml/h flow rate.
  • the sample was removed from the cell and biofilm fluorescence was detected by confocal laser scanning microscope.
  • the dyed membranes were analyzed by a confocal laser scanning microscope.
  • Enzymes concentrations were determined by preliminary experiment that was performed to screen for concentrations allowing complete degradation of C-Modelin-1 within 1-2 hours. 10 ⁇ of enzyme solution with varying concentrations were added to 90 ⁇ of peptide solution (0.56 mg/ml) and enzymatic degradation of the peptide was monitored by RP-HPLC.
  • RO Membrane performance analysis The properties of RO membranes were evaluated before and after modification to estimate the effect of immobilization of AMPs on membrane performance. Properties that were measured are: Permeability (Lp) , permeate flux, and salt rejection.
  • the membrane properties were measured in a cross-flow system equipped with two membrane cells.
  • the system can generate a pressure up to 25 bar using nitrogen gas.
  • the system has a container of -1.8L, and a pump that can generate flow up to 1350 mL/minute.
  • the pressure inside the system can be controlled by a Nitrogen gas inlet and a pressure gauge; the temperature can be monitored with a water bath and a thermocouple thermometer.
  • the parameters for all the analyses are temperature of 2 °C, pressure of 15.2 bar, feed velocity of 1360 mL/minute, as indicated by the manufacturer in the membrane product sheet as the parameters for the membrane tests.
  • the membrane area in these tests is 16.8cm 2 (8.3cm X 2.2cm) .
  • the pure water permeability analysis was carried out using LE-400 RO membranes that were compacted for 5-8 hours before the test with DDW water in the test 1 s conditions. The measurements were done with DDW. that were filled in the feed container, and after reaching a constant permeate flow. The permeate was collected 5-8 times for 5-12 minutes each time, and was weighted using analytical scale. The volume flux (Jv) was calculated, and by dividing it with the applied pressure the Lp value was obtained.
  • the salt rejection measurements were done on the membranes after 5-8 hours of compacting with DDW. NaCl was used as the tested salt in the concentration of 2000 ppm.
  • the permeate was collected 7 times, for 10-12 minutes each time, and the conductivity was measured for each permeate collection.
  • the feed was collected just before each measurement, to determine the feed conductivity since each measurement changed the salt concentration in the feed.
  • the solution collections conductivities were measured by conductivity meter (WTW GmbH & Co., Weilheim, Germany) .
  • Fmoc deprotection was achieved by treatment with 20% piperidine in DMF for 5 minutes and again for 25 minutes. After completion the resin was washed 4-5 times with DMF or NMP and 2 times with DCM, each wash lasted 0.5-2 minutes.
  • Amino acid coupling procedure 4-5 equivalents of protected amino acid and 4-5 eq of coupling reagent PyBOP or HBTU, respectively, were dissolved in DMF or DMF: DCM 1:1 solution. 8 eq of DIEA were added to the solution. After mixing it for 10 minutes the solution was added to the resin (previously swelled) and mixed for 2-3 hours for manual synthesis (using lab suspension mixer, MRC, Holon, Israel) or 1.5 hours for automated synthesis. After the reaction was completed the resin was washed 3 times with DMF and 2 times with DCM.
  • Amino acid coupling to Wang resin The coupling performed using the symmetrical anhydride method. 10 eq of protected amino acid were dissolved in DCM (DMF was added if required) . 5 eq of DIC were added to the solution and it was mixed for 20 minutes at 0°C. The DCM was evaporated using rotavapor, the remained mixture was dissolved in minimal amount of DMF and added to the resin. 0.1 eq of DMAP in DMF solution were added to the reaction vessel and it was mixed for 2-20 hours. After completion, the resin was washed 3 times with DMF and 2 times with DCM.
  • Solution volume was reduced to 2-4 ml using stream of nitrogen gas, then the peptide was precipitated by adding cold methyl tert-butyl ether (10 times the remained cocktail volume) , centrifuged for 10 minutes at 2500 rpm (Labofuge 400 centrifuge, Thermo Fisher, Scientific, Waltham, Massachusetts) and the tert-butyl methyl ether was removed. The peptide was washed 2 more times with tert-butyl methyl ether (3 more, if 1 , 2 -ethanedithiol was used in the cleavage cocktail) .
  • the peptide was dissolved in DDW or if necessary, acetic acid or acetonitrile (or both) were added, so that acetonitrile volume did not exceed 10% of the final volume.
  • the dissolved peptide was then freeze- dried on a lyophilizer (Labconco FreeZone 2.5 Plus, Kansas City, Missouri) and analyzed by MALDI-TOF mass spectrometry and RP-HPLC.
  • Table 4 lists peptides that were synthesized and used in the present invention and specifies their sequence, resin used for SPPS and scale of synthesis.
  • Some antimicrobial peptides as prepared according to the methods described above, were modified to include an arm molecule at their amino terminus, to test the effect of adding an arm on the antimicrobial activity.
  • the arms included additional amino acids (CG3, G4, etc.) , as well as 6-aminohexanoic acid (marked as X) and CX.
  • CG3, G4, etc. additional amino acids
  • 6-aminohexanoic acid marked as X
  • CX 6-aminohexanoic acid
  • CX 6-aminohexanoic acid
  • the effect of linking the arm to a peptide, on the antimicrobial activity of the peptides was assessed by measuring the peptide activity in 96-microtitter plates in solution and comparing to activities of the normal peptides. Experiments were performed in water and in 3% NaCl solution. Table 6 presents the antimicrobial activity (IC 50 ) of peptide-arm systems, in water and in 3% NaCl solution. Values were extracted from dose-response curves.
  • Example 1 Screening peptides for suitability in preventing biofilm formation
  • Figure 1 shows the average biofilm formed by Enterobacter in the presence of C-Modelin-l ⁇ -Ala, (All- D) -C-Modelin- 1 and C- Modelin. IC 50 values were calculated from the graphs of Figure 1 and are presented in Table 7.
  • the modified peptide (D) -C-Modelin-1 exhibited biofilm inhibition activity similar to the activity of the original, unmodified, C-Modelin-1 peptide.
  • the IC 50 value of C-Modelin-l- Ala was lower than that of C-Modelin-1, indicating that insertion of the unnatural amino acid ⁇ - Ala to the sequence enhanced the antimicrobial activity of the peptide.
  • Peptide stability The enzymatic degradation was monitored at a fixed temperature of 25°C by RP-HPLC at 220 nm, as described before. Elution gradient started with 85% A/15% B for 5 minutes continued with 30% A/70% B for 35 minutes and ended with 5% A - 95% B for 12 minutes .
  • sulfoNHS N-hydroxysulfosuccinimide sodium salt
  • EDC N-(3- dimethylaminopropyl) - ' -ethylcarbodiimide hydrochloride
  • MI 6-maleimidohexanoic acid
  • the solution was added to the modified membrane prepared in the previous step, which was covered and nitrogen gas was bubbled through the solution for 5 minutes to prevent oxidation of the thiol groups . After 2.5 hours on the shaker the membrane was washed as described in step II.
  • Modelin-1 Modelin-1
  • additional PEGylated peptides as listed in Table 11 below was prepared on SPPS, as described in the general preparation methods section above.
  • the PEGylation coupling step was performed by using Fmoc-NH-PEG 3 ooo-CO-NHS or Trityl-S-C 2 H 4 -NH-PEG-COOSu (Rapp- polymere, Tubingen, Garmany) .
  • Fmoc-NH-PEG3000-CO-NHS coupling of Fmoc-Cys (Trityl) -OH was performed.
  • the compounds were further characterized by MALDI-TOF mass spectrometry and analytical HPLC using Ci 8 column for polymers (300 A voids) .
  • the PEGylated peptide N- terminal Fmoc was deprotected with 20% piperidine in DMF. Final cleavage from the resin was achieved by a mixture of 95% trifluoroacetic acid (TFA) ( 2.5% triisopropylsilane and 2.5% water for 2 hours. After cleavage of the protecting groups, peptides were precipitated by addition of cold diethyl ether and dried with N 2 gas . The crude PEGylated peptide was dissolved in water, and dried in lyophilizer over night (-82°C, 0.01 mbar) . Then, the crude PEG-peptides were purified by reversed-phase HPLC. The final products were more than 40% pure. Table 11 below specifies the sequences and purities of PEG-peptides that were prepared.
  • a PEGylated peptide (HS-PEG-D-Modelin-1) was prepared, and its inhibitory potency compared to that of the 'normal' peptide All-D-Modelin-1.
  • Peptides were diluted in 2-fold serial dilutions, and the antibacterial activity of the peptides was determined in sterile 96 -multititter plates.
  • the IC 50 that was calculated from this experiment was 0.62ug/ml, much lower than the D-Modelin-1. This means that the PEG tether slightly increased the antimicrobial effect of peptide D-Modelin-1.
  • the maleimide linker was linked to a reverse osmosis LE-400 membrane as described for attachment of diamine linkers in Example 2 (3-step procedure) , by using 30 mM concentration of N- (2 -Aminoethyl) -maleimide trifluoroacetate .
  • the solution was added to the membrane (2 ml/1 cm2 membrane; previously modified with Maleimide linker) , and the reaction was proceeded overnight; workup was performed as described for peptide attachment in Example 2 (3 -steps procedure) .
  • the loading of RO membranes with peptides was determined in two ways: in the first, by changes in the free carboxylic group concentration oh the surface of the polyamide membrane, in the second by measuring enzymatic cleavage of 7-amino-4-methylcoumarine (AMC) residue.
  • AMC 7-amino-4-methylcoumarine
  • the concentration of free amine residues was calculated before and after attachment of JeffamineTM 50 o and MI to the membrane. According to these calculations, the free amine concentration on the membrane surface increased after attachment of the arms and then decreased after modification with MI.
  • the concentration of JeffamineTM attached to the membrane is 5.55xl0 "9 mol/cm 2 . After attachment of MI, the free amines concentration decreased to a lower level than the ' concentration before modification. This indicates that the MI is attached to the free amines of the membrane and of the arm with calculated yield of 50%.
  • the cleavage reaction of AMC from the unbound peptide terminated completely after 2 days, while the cleavage from the immobilized peptide continued over 7 days.
  • the cleavage of AMC from the immobilized peptide required a longer period of time and the fluorescence values were lower because the access of the enzyme to the substrate was restricted.
  • Figure 3 presents the biofilm volume on RO membrane immobilized according to Scheme 3 (marked “Maleimide-cys-PEG-Modelin 1" and “C-cys-PEG- Modelin 1", regular linear immobilizaiton (3 steps method, as in Example 2 ) ) , in comparison to non-modified membrane (marked “control").
  • the membranes washed 3x10 minutes in DDW using sonication.
  • the soxhlet extractor was performed in order to clean the membrane and to confirm that the monomers did not adsorb to the surface of the membrane but have been attached covalently on the membrane surface.
  • the soxhlet extractor was done in methanol for 3 hours .
  • the membranes showed before and after soxhlet the same IR spectrum.
  • sulfoNHS N- hydroxysulfosuccinimide sodium salt
  • EDC N- (3-dimethylaminopropyl) -N 1 -ethylcarbodiimide hydrochloride
  • step 1 The results indicate that the graft polymerization (step 1) was successful, increasing carboxyl groups by 7- fold, and the reaction with 1, 4-butadiamine (step 2) had 82% yield.
  • Figures 4 and 5 show the biovolume of biofilm on RO membranes modified with Cys-Modelin-1, whereas in Figure 4: (A) is an unmodified membrane (control), (B) is after Graft polymerization (GP) , (C) is after GP and 1,4- butadiamine, (D) is after GP, 1 , 4 -butadiamine and MI (maleimide-hexanoic acid), and (E) is after GP, 1,4- butadiamine, MI and C-Modelin-1.
  • Figure 5 shows the volume of the biofilm formed on the examined membranes. As can be seen, immobilization with the peptide reduced biofilm growth by 65%; immobilization with maleimide group reduced biofilm growth by 95%.
  • FIG. 6 Another example for immobilization through multivalent system is shown in Figure 6, showing the volume of the biofilm by graft polymerization with 0.2:0.2 M MA : PEGM and immobilization with All-D-Cys- Modelin-1. The results show good biofilm inhibition for peptide Cys-Modelin-1 (80%) . The inhibition was very much dependent of the graft polymerization step: Grafting by 0.2:0.2 M of monomers PEGMA:MA (see Scheme 6 for monomer structures) gave the best results.
  • FILMTEC LE-400 RO membranes were graft polymerized as in Example 4, with the two acrylic polymers being PEGMA: MA in a 0.2:0.8M concentration respectively.
  • Figure 7 shows the biovolume according to an Enterobacter assay of the various stages of prepared membrane: After stage (1) of the graft polymerization (grafting) , after the attachment of MI linker of aminoethyl-maleimide (graft_MI) , and after the attachment of HS-PEG3000-D-Modelin-l (graft_MI_S-PEG-D-Modelinl) .
  • stage (1) of the graft polymerization (grafting) after the attachment of MI linker of aminoethyl-maleimide (graft_MI)
  • HS-PEG3000-D-Modelin-l HS-PEG3000-D-Modelin-l
  • graft_MI_S-PEG-D-Modelinl HS-PEG3000-D-Modelin-l

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des membranes pour le traitement antimicrobien de l'eau, comprenant une membrane de traitement de l'eau, liées de façon covalente à un ou plusieurs peptides antimicrobiens ou dérivés de ceux-ci, soit directement soit via une ou plusieurs molécules d'ancrage. La présente invention concerne en outre un procédé de préparation de membranes antimicrobiennes, et leurs utilisations dans des applications de traitement de l'eau.
PCT/IL2010/001034 2009-12-07 2010-12-07 Membranes pour traitement antimicrobien de l'eau et leur production WO2011070573A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10835606.4A EP2509614A4 (fr) 2009-12-07 2010-12-07 Membranes pour traitement antimicrobien de l'eau et leur production
US13/514,103 US9175036B2 (en) 2009-12-07 2010-12-07 Antimicrobial water treatment membranes and production thereof
IL220181A IL220181B (en) 2009-12-07 2012-06-05 Antibacterial membranes for water treatment and their preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26709909P 2009-12-07 2009-12-07
US61/267,099 2009-12-07

Publications (1)

Publication Number Publication Date
WO2011070573A1 true WO2011070573A1 (fr) 2011-06-16

Family

ID=44145170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/001034 WO2011070573A1 (fr) 2009-12-07 2010-12-07 Membranes pour traitement antimicrobien de l'eau et leur production

Country Status (3)

Country Link
US (1) US9175036B2 (fr)
EP (1) EP2509614A4 (fr)
WO (1) WO2011070573A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172547A1 (fr) 2011-06-15 2012-12-20 Ben-Gurion University Of The Negev Research And Development Authority Immobilisation de polymères antimicrobiens sur une membrane ro pour réduire la croissance de biofilm et l'encrassement biologique
RU2605965C1 (ru) * 2015-07-22 2017-01-10 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ твердофазной экстракции красителя толуидинового синего
EP3119501A4 (fr) * 2014-03-19 2017-04-12 E.W.-Hydrophilic Processes Ltd Filtre

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070573A1 (fr) * 2009-12-07 2011-06-16 Ben-Gurion University Of The Negev Research And Development Authority Membranes pour traitement antimicrobien de l'eau et leur production
US10384167B2 (en) 2013-11-21 2019-08-20 Oasys Water LLC Systems and methods for improving performance of osmotically driven membrane systems
WO2015084279A1 (fr) 2013-12-03 2015-06-11 Istanbul Teknik Universitesi Membrane antibactérienne et procédé pour la produire
US10793762B2 (en) 2017-08-15 2020-10-06 Saudi Arabian Oil Company Layered double hydroxides for oil-based drilling fluids
US10988659B2 (en) 2017-08-15 2021-04-27 Saudi Arabian Oil Company Layered double hydroxides for oil-based drilling fluids
US10745606B2 (en) 2017-08-15 2020-08-18 Saudi Arabian Oil Company Oil-based drilling fluid compositions which include layered double hydroxides as rheology modifiers
EP3668940A1 (fr) 2017-08-15 2020-06-24 Saudi Arabian Oil Company Tensioactifs thermiquement stables pour fluides de forage à base d'huile
US10647903B2 (en) 2017-08-15 2020-05-12 Saudi Arabian Oil Company Oil-based drilling fluid compositions which include layered double hydroxides as rheology modifiers and amino amides as emulsifiers
US10640696B2 (en) 2017-08-15 2020-05-05 Saudi Arabian Oil Company Oil-based drilling fluids for high pressure and high temperature drilling operations
US10876039B2 (en) 2017-08-15 2020-12-29 Saudi Arabian Oil Company Thermally stable surfactants for oil based drilling fluids
US10676658B2 (en) 2017-08-15 2020-06-09 Saudi Arabian Oil Company Oil-based drilling fluids for high pressure and high temperature drilling operations
JP2021502930A (ja) 2017-10-26 2021-02-04 アドバンシックス・レジンズ・アンド・ケミカルズ・リミテッド・ライアビリティ・カンパニーＡｄｖａｎｓｉｘ Ｒｅｓｉｎｓ ＆ Ｃｈｅｍｉｃａｌｓ Ｌｌｃ オゾン消去のための多層パッケージ構造
CN109865438A (zh) * 2017-12-01 2019-06-11 俞小峰 一种抗菌稳定型纳滤膜材料的制备方法
CA3142878A1 (fr) * 2019-06-19 2020-12-24 Huntsman Petrochemical Llc Performance synergique de melanges d'amines dans le controle de schistes
CN112108012A (zh) * 2020-09-29 2020-12-22 湖南澳维环保科技有限公司 一种抗菌聚酰胺反渗透复合膜及其制备方法
CN117160254B (zh) * 2023-10-31 2024-01-23 湖南沁森高科新材料有限公司 一种反渗透复合膜及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050247A1 (en) * 2000-06-16 2003-03-13 Kuhner Carla H. Chemically-modified peptides, compositions, and methods of production and use
US7176276B2 (en) * 2003-10-20 2007-02-13 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US20090022888A1 (en) * 2007-07-16 2009-01-22 Allvivo Vascular, Inc. Antimicrobial constructs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197529B1 (en) * 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
US7172276B2 (en) * 2004-12-10 2007-02-06 Xerox Corporation Heterogeneous low energy gel ink composition
EP1991245A2 (fr) * 2006-02-15 2008-11-19 Massachusetts Institute of Technology (MIT) Dispositifs medicaux et revetements composes de peptides antimicrobiens non infiltrants
JP2009165949A (ja) 2008-01-15 2009-07-30 Japan Organo Co Ltd 抗菌性分離膜、その製造方法、および抗菌性分離膜の製造装置
CA2745499A1 (fr) * 2008-12-05 2010-06-10 Angiochem Inc. Conjugues therapeutiques peptidiques et leurs applications
WO2011070573A1 (fr) * 2009-12-07 2011-06-16 Ben-Gurion University Of The Negev Research And Development Authority Membranes pour traitement antimicrobien de l'eau et leur production
US20140238939A1 (en) * 2011-06-15 2014-08-28 Wisconsin Alumni Research Foundation Immobilization of antimicrobial polymers on ro membrane to reduce biofilm growth and biofouling

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050247A1 (en) * 2000-06-16 2003-03-13 Kuhner Carla H. Chemically-modified peptides, compositions, and methods of production and use
US7176276B2 (en) * 2003-10-20 2007-02-13 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US20090022888A1 (en) * 2007-07-16 2009-01-22 Allvivo Vascular, Inc. Antimicrobial constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI ET AL., ANTIMICROBIAL NANOMATERIALS FOR WATER DISINFECTION AND MICROBIAL CONTROL: POTENTIAL APPLICATIONS AND IMPLICATIONS, 27 August 2008 (2008-08-27), DEPARTMENT OF CIVIL AND ENVIRONMENTAL ENGINEERING, RICE UNIVERSITY, MS 317, XP025584029 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172547A1 (fr) 2011-06-15 2012-12-20 Ben-Gurion University Of The Negev Research And Development Authority Immobilisation de polymères antimicrobiens sur une membrane ro pour réduire la croissance de biofilm et l'encrassement biologique
EP3119501A4 (fr) * 2014-03-19 2017-04-12 E.W.-Hydrophilic Processes Ltd Filtre
RU2605965C1 (ru) * 2015-07-22 2017-01-10 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ твердофазной экстракции красителя толуидинового синего

Also Published As

Publication number Publication date
EP2509614A1 (fr) 2012-10-17
US20120325748A1 (en) 2012-12-27
US9175036B2 (en) 2015-11-03
EP2509614A4 (fr) 2014-08-06

Similar Documents

Publication Publication Date Title
US9175036B2 (en) Antimicrobial water treatment membranes and production thereof
US20140238939A1 (en) Immobilization of antimicrobial polymers on ro membrane to reduce biofilm growth and biofouling
Zhang et al. Silver–PEGylated dendrimer nanocomposite coating for anti-fouling thin film composite membranes for water treatment
Li et al. Surface modification of PES ultrafiltration membrane by polydopamine coating and poly (ethylene glycol) grafting: Morphology, stability, and anti-fouling
Perreault et al. Biofouling mitigation in forward osmosis using graphene oxide functionalized thin-film composite membranes
Saeki et al. Development of antibacterial polyamide reverse osmosis membrane modified with a covalently immobilized enzyme
CN109232719B (zh) 一种pH响应的抗菌肽及其制备方法和应用
Cheng et al. Graphene oxide-functionalized membranes: the importance of nanosheet surface exposure for biofouling resistance
US10676509B2 (en) Surface-immobilized antimicrobial peptoids
Dang et al. Biocompatible and antifouling coating of cell membrane phosphorylcholine and mussel catechol modified multi-arm PEGs
Statz et al. Surface-immobilised antimicrobial peptoids
Piatkovsky et al. A zwitterionic block-copolymer, based on glutamic acid and lysine, reduces the biofouling of UF and RO membranes
Shtreimer Kandiyote et al. Synergy on surfaces: Anti-biofouling interfaces using surface-attached antimicrobial peptides PGLa and magainin-2
Shtreimer Kandiyote et al. Grafted polymer coatings enhance fouling inhibition by an antimicrobial peptide on reverse osmosis membranes
US8710179B2 (en) Compositions and methods for concentrating and depleting microorganisms
US20130040357A1 (en) Hydrogel Precursor Formulation and Production Process Thereof
CN110169950B (zh) 一种可注射性抗菌肽水凝胶及其制备方法
Sabir et al. Hyperbranched polyethyleneimine induced polycationic membranes for improved fouling resistance and high RO performance
JP5463515B2 (ja) 抗微生物ペプチドを固定化した素材
Mohanraj et al. Ink-jet printing-assisted modification on polyethersulfone membranes using a UV-reactive antimicrobial peptide for fouling-resistant surfaces
Bellotto et al. Nanotubes and water-channels from self-assembling dipeptides
US11154636B2 (en) Antimicrobial biopolymer compositions, methods of synthesis, and applications of use
US20080237135A1 (en) Pb2+- ion binding by polyacid- based nanoparticles
CN110028557B (zh) 一种Ce6标记的双链抗菌肽及其合成方法和应用
Gershkovich Zuckerberg Institute for Water Research

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10835606

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 220181

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010835606

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13514103

Country of ref document: US